Ultra Nasdaq Biotechnology 2X ETF (BIB)

N/A +N/A (N/A)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume N/A
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

The index is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies. Under normal circumstances, the fund will obtain leveraged exposure to at least 80% of its total assets in components of the index or in instruments with similar economic characteristics. The fund is non-diversified.

svertical1
svertical1 Jun. 23 at 11:31 PM
$BIB $CMPS $LXRX $VRTX Vertex had poor study design. Sciatica pain episode duration lasts on average 10 days. They asked for placebo effect at 12 weeks, ‘ how’s the pain now’. You have to look at the hourly/daily pain relief while patient would be experiencing pain, not some arbitrary ‘months’ later date.
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jun. 23 at 9:50 PM
$CMPS Example: A $VRTX showed even WORSE BASELINE EFFECTS OF 2 at 12 weeks and even worse vs Placebo at 1.98. For their non opioid pain drug, results from phase 2 on December 19th 2024(last yr). THE STOCK PLUMMETS OVER 10%. Then Phase 3 results come, also don't impress much. A MONTH LATER FDA APPROVES THE SAME DRUG ON JANUARY 30th 2025. THE STOCK SKYROCKETS FOR DAYS, I RECALL THIS SPECIFICALLY BECUASE I AM IN A NON OPIOID DRUG STOCK $LXRX. LITERALLY ABOUT A MONTH LATER THE SAME 'DISAPPOINTING STREET EXPECTED RESULTS' WERE MEDICALLY SIGNIFICANT ENOUGH TO FDA GREENLIGHT IT. WE MISSED MAYBE BY A POINT AT 4 points vs 5 expected. (3.6) YOU HAVE TO BE MENTALLY UNSTABLE IF YOU THINK PRO PSYCLOCIBIN ROBERT KENNDY WILL NOT FIND THESE RESULTS MEDICALLY SIGNIFICANT FOR APPROVAL. $BIB
1 · Reply
macrossluvsrobotech
macrossluvsrobotech Jun. 19 at 3:24 PM
$CMPS $BIB qhttps://www.livescience.com/health/mind/one-psychedelic-psilocybin-dose-eases-depression-for-years-study-reveals
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jun. 17 at 3:04 PM
$CMPS = "Compass Pathways is expecting to release the top-line, 6-week (primary endpoint) results for their COMP005 Phase 3 trial (part of the larger COMP360 psilocybin treatment program for treatment-resistant depression) in late June 2025. " Single psilocybin trip delivers two years of depression relief for cancer patients Phase 2 trial reveals that a single dose of psilocybin offers long-term relief from symptoms of depression and anxiety. "Yes, RFK Jr. has expressed support for the therapeutic potential of psychedelics, including psilocybin, and has advocated for their use in mental health treatment. " "Criticism of FDA policies: He has criticized the FDA for its "aggressive suppression of psychedelics". " Now he runs this agency. https://www.sciencedaily.com/releases/2025/06/250616040215.htm $MRK $GILD $BIB
0 · Reply
jjon2121
jjon2121 May. 29 at 12:02 AM
$LABU $LABD $XBI $IBB $BIB Is this the reason for the AH turnaround? https://www.cnbc.com/2025/05/29/court-strikes-down-trump-reciprocal-tariffs.html
2 · Reply
macrossluvsrobotech
macrossluvsrobotech May. 15 at 1:06 PM
$LXRX $VTRS $NVO $BIB Two weeks ago. Edelman unofficially giving the new administration a second shot at considering T1D for Sota. Nice. Smells like Biden bias for last decision. Now under Dr Martin Makary at the helm and anti jabby JFK jr, looking good. https://www.linkedin.com/posts/taking-control-of-your-diabetes_update-from-dr-steve-edelman-this-morning-activity-7323060775802064897--mMx?utm_source=share&utm_medium=member_ios&rcm=ACoAAAsxtNMB_-3m9veO28z6qXYyCblWycfZlRA
2 · Reply
macrossluvsrobotech
macrossluvsrobotech May. 14 at 11:31 AM
$FET.X $BIB $GILD $NVDA YOUR PERSONAL MEDICAL / HEALTH AI AGENT WITH THE IMMUTABLE LEDGER TECHNOLOGY (BLOCKCHAIN) BAKED INTO IT, UNLIKE ANY OTHER AI TECH OUT THERE = TRULY DEMOCRATIC AND FREE FOR GOVT USE THE ONLY AND FIRST AI AGENT TECHH FOR WEB3
0 · Reply
SnoopDawg
SnoopDawg May. 12 at 12:50 AM
$BIB exec order will cause pharma to raise prices overseas to match domestic. More money for pharma.
0 · Reply
macrossluvsrobotech
macrossluvsrobotech May. 9 at 10:55 PM
$GILD $BIB "HIV Drugs Linked to Lower Alzheimer’s Risk" whttps://neurosciencenews.com/nrtis-hiv-alzheimers-28859/
0 · Reply
jjon2121
jjon2121 Apr. 21 at 12:02 PM
$LABU $LABD $XBI $IBB $BIB Once again. Here is the biggest problem folks. Companies shying away from full buyouts. Most bullish Bio trend been pretty weak since Nov. https://www.bioworld.com/articles/719338-biopharma-m-and-as-plunge-in-q1-while-6686b-in-deals-beats-2024-average?v=preview
2 · Reply
Latest News on BIB
Healthcare Sector Checkup As U.S. Looks To Change Regulations

May 30, 2025, 3:30 PM EDT - 25 days ago

Healthcare Sector Checkup As U.S. Looks To Change Regulations

AGNG ARKG BBC BBH BBP BIS BMED

Seeking Stocks With Vitality In The Volatile Healthcare Sector

Feb 25, 2025, 11:06 AM EST - 4 months ago

Seeking Stocks With Vitality In The Volatile Healthcare Sector

IBB XLV AGNG ARKG BBC BBH BBP

Will The Next Batch Of Tech Earnings Encourage Investors To Rotate Back In?

Jul 30, 2024, 2:30 AM EDT - 11 months ago

Will The Next Batch Of Tech Earnings Encourage Investors To Rotate Back In?

AAPL AMZN ANSS BA FFIV GOOGL HSY

Equity CEFs/ETFs: Top Picks For 2024 - Part II

Jan 5, 2024, 11:01 AM EST - 1 year ago

Equity CEFs/ETFs: Top Picks For 2024 - Part II

AIO AIQ DIG EOI ETW EXG HQH

Why Now Could Be The Time To Consider Neuroscience Investments

Aug 27, 2022, 4:45 AM EDT - 3 years ago

Why Now Could Be The Time To Consider Neuroscience Investments

ARKG BBH FBT GNOM HELX IBB IBBQ

svertical1
svertical1 Jun. 23 at 11:31 PM
$BIB $CMPS $LXRX $VRTX Vertex had poor study design. Sciatica pain episode duration lasts on average 10 days. They asked for placebo effect at 12 weeks, ‘ how’s the pain now’. You have to look at the hourly/daily pain relief while patient would be experiencing pain, not some arbitrary ‘months’ later date.
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jun. 23 at 9:50 PM
$CMPS Example: A $VRTX showed even WORSE BASELINE EFFECTS OF 2 at 12 weeks and even worse vs Placebo at 1.98. For their non opioid pain drug, results from phase 2 on December 19th 2024(last yr). THE STOCK PLUMMETS OVER 10%. Then Phase 3 results come, also don't impress much. A MONTH LATER FDA APPROVES THE SAME DRUG ON JANUARY 30th 2025. THE STOCK SKYROCKETS FOR DAYS, I RECALL THIS SPECIFICALLY BECUASE I AM IN A NON OPIOID DRUG STOCK $LXRX. LITERALLY ABOUT A MONTH LATER THE SAME 'DISAPPOINTING STREET EXPECTED RESULTS' WERE MEDICALLY SIGNIFICANT ENOUGH TO FDA GREENLIGHT IT. WE MISSED MAYBE BY A POINT AT 4 points vs 5 expected. (3.6) YOU HAVE TO BE MENTALLY UNSTABLE IF YOU THINK PRO PSYCLOCIBIN ROBERT KENNDY WILL NOT FIND THESE RESULTS MEDICALLY SIGNIFICANT FOR APPROVAL. $BIB
1 · Reply
macrossluvsrobotech
macrossluvsrobotech Jun. 19 at 3:24 PM
$CMPS $BIB qhttps://www.livescience.com/health/mind/one-psychedelic-psilocybin-dose-eases-depression-for-years-study-reveals
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jun. 17 at 3:04 PM
$CMPS = "Compass Pathways is expecting to release the top-line, 6-week (primary endpoint) results for their COMP005 Phase 3 trial (part of the larger COMP360 psilocybin treatment program for treatment-resistant depression) in late June 2025. " Single psilocybin trip delivers two years of depression relief for cancer patients Phase 2 trial reveals that a single dose of psilocybin offers long-term relief from symptoms of depression and anxiety. "Yes, RFK Jr. has expressed support for the therapeutic potential of psychedelics, including psilocybin, and has advocated for their use in mental health treatment. " "Criticism of FDA policies: He has criticized the FDA for its "aggressive suppression of psychedelics". " Now he runs this agency. https://www.sciencedaily.com/releases/2025/06/250616040215.htm $MRK $GILD $BIB
0 · Reply
jjon2121
jjon2121 May. 29 at 12:02 AM
$LABU $LABD $XBI $IBB $BIB Is this the reason for the AH turnaround? https://www.cnbc.com/2025/05/29/court-strikes-down-trump-reciprocal-tariffs.html
2 · Reply
macrossluvsrobotech
macrossluvsrobotech May. 15 at 1:06 PM
$LXRX $VTRS $NVO $BIB Two weeks ago. Edelman unofficially giving the new administration a second shot at considering T1D for Sota. Nice. Smells like Biden bias for last decision. Now under Dr Martin Makary at the helm and anti jabby JFK jr, looking good. https://www.linkedin.com/posts/taking-control-of-your-diabetes_update-from-dr-steve-edelman-this-morning-activity-7323060775802064897--mMx?utm_source=share&utm_medium=member_ios&rcm=ACoAAAsxtNMB_-3m9veO28z6qXYyCblWycfZlRA
2 · Reply
macrossluvsrobotech
macrossluvsrobotech May. 14 at 11:31 AM
$FET.X $BIB $GILD $NVDA YOUR PERSONAL MEDICAL / HEALTH AI AGENT WITH THE IMMUTABLE LEDGER TECHNOLOGY (BLOCKCHAIN) BAKED INTO IT, UNLIKE ANY OTHER AI TECH OUT THERE = TRULY DEMOCRATIC AND FREE FOR GOVT USE THE ONLY AND FIRST AI AGENT TECHH FOR WEB3
0 · Reply
SnoopDawg
SnoopDawg May. 12 at 12:50 AM
$BIB exec order will cause pharma to raise prices overseas to match domestic. More money for pharma.
0 · Reply
macrossluvsrobotech
macrossluvsrobotech May. 9 at 10:55 PM
$GILD $BIB "HIV Drugs Linked to Lower Alzheimer’s Risk" whttps://neurosciencenews.com/nrtis-hiv-alzheimers-28859/
0 · Reply
jjon2121
jjon2121 Apr. 21 at 12:02 PM
$LABU $LABD $XBI $IBB $BIB Once again. Here is the biggest problem folks. Companies shying away from full buyouts. Most bullish Bio trend been pretty weak since Nov. https://www.bioworld.com/articles/719338-biopharma-m-and-as-plunge-in-q1-while-6686b-in-deals-beats-2024-average?v=preview
2 · Reply
macrossluvsrobotech
macrossluvsrobotech Apr. 20 at 12:48 AM
$LXRX + $NVO THEY MAKE A DEAL FOR LEXICONS ORAL WEIGHT LOSS PILL TO COMPETE WITH $LLY. BUY OUT?? Novo Nordisk and Lexicon Deal = "Novo Nordisk to license obesity drug from Lexicon in up to $1 billion deal By Sneha S K March 28, 20258:18 AM PDTUpdated 22 days ago" https://www.reuters.com/business/healthcare-pharmaceuticals/lexicon-license-obesity-drug-novo-nordisk-up-1-billion-deal-2025-03-28/ About LX9851 "LX9851 is an orally delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders. https://investors.lexpharma.com/news-releases/news-release-details/lexicon-present-preclinical-vivo-efficacy-data-demonstrating/" "Novo Nordisk Is Getting Absolutely Destroyed" https://futurism.com/neoscope/novo-nordisk-getting-destroyed "Novo Nordisk shares slump following Eli Lilly’s weight-loss pill success" https://finance.yahoo.com/news/novo-nordisk-shares-slump-following-140751424.html $HIMS $LLY $BIB
3 · Reply
macrossluvsrobotech
macrossluvsrobotech Apr. 15 at 4:47 PM
$BIB $HIMS $LLY $LXRX $NVO Just the messenger.
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Apr. 15 at 11:58 AM
$LXRX + $NVO " Pfizer Halts Obesity-Drug Development. What It Means for Eli Lilly, Novo Nordisk." https://www.barrons.com/articles/pfizer-eli-lilly-novo-stock-price-obesity-drug-304c7c2f Novo Nordisk to license obesity drug from Lexicon in up to $1 billion deal By Sneha S K March 28, 20258:18 AM PDTUpdated 13 days ago https://www.reuters.com/business/healthcare-pharmaceuticals/lexicon-license-obesity-drug-novo-nordisk-up-1-billion-deal-2025-03-28/ $BIB $LLY $HIMS
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Apr. 11 at 3:44 PM
$LXRX $LXRX +$NVO Maybe this is why we got that 1 Bil no questions asked from $NVO , it wasn't just a more competitive and better weight loss treatment = LX9851 : Not Just Weight and Diabetes /but Alzheimer's as well: "GLP-1 Drugs Might Cut Dementia Risk in Half F. Perry Wilson, MD, MSCE DISCLOSURES | April 07, 2025" https://www.medscape.com/viewarticle/glp-1-drugs-might-cut-dementia-risk-half-2025a10008bs?form=fpfLX9851 stimulates the body to generate GLP-1, Ozempic and Jardiance IMITATE and create an ARTIFICIAL GLP-1, while LX9851 makes the REAL DEAL: "Diabetes drugs like Ozempic or Jardiance may slash Alzheimer's risk" https://www.medicalnewstoday.com/articles/diabetes-drugs-like-ozempic-or-jardiance-may-slash-alzheimers-risk $BIB $LXRX + $NVO 1Bil Deal = https://www.reuters.com/business/healthcare-pharmaceuticals/lexicon-license-obesity-drug-novo-nordisk-up-1-billion-deal-2025-03-28/ $LLY $HIMS
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Apr. 10 at 1:39 PM
$LXRX + $NVO Novo Nordisk to license obesity drug from Lexicon in up to $1 billion deal By Sneha S K March 28, 20258:18 AM PDTUpdated 13 days ago https://www.reuters.com/business/healthcare-pharmaceuticals/lexicon-license-obesity-drug-novo-nordisk-up-1-billion-deal-2025-03-28/ $BIB
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Apr. 9 at 7:55 PM
$LXRX + $NVO $BIB https://www.reuters.com/business/healthcare-pharmaceuticals/lexicon-license-obesity-drug-novo-nordisk-up-1-billion-deal-2025-03-28/
1 · Reply
macrossluvsrobotech
macrossluvsrobotech Apr. 4 at 11:37 AM
$LXRX Tariff Free Safety trade with a 1Billion Dollars in the bank. Hedge and Alpha in any economical condition. LONG. $LXRX They thought Tariffs would save them, but then you have this: "Trump imposed a 10% tariff on most U.S. imports, as well as much higher levies on dozens of rivals and allies alike, but temporarily exempted some goods, including pharmaceuticals, benefiting major exporters including India, Japan and Ireland." https://www.reuters.com/world/india/indian-pharma-stocks-defy-market-slump-us-tariffs-exemption-2025-04-03/ Shorts can't fk with math: No one can : $NVO HAS 1 BILLION DOLLARS ON THE TABLE. THERE ARE : $LXRX 361,492,295 shares. $1 Billion from $NVO divided by: 361,492,295 $LXRX shares= $2.76 a $LXRX share. JUST ON THIS DEAL ALONE, DISCOUNTING THE NON OPIOD GOING ONTO PHASE 3. https://www.investors.com/news/technology/novo-nordisk-lexicon-pharmaceuticals-obesity-treatment/ $HIMS $LLY $BIB Bullish
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Apr. 4 at 11:30 AM
$LXRX They thought Tariffs would save them, but then you have this: "Trump imposed a 10% tariff on most U.S. imports, as well as much higher levies on dozens of rivals and allies alike, but temporarily exempted some goods, including pharmaceuticals, benefiting major exporters including India, Japan and Ireland." https://www.reuters.com/world/india/indian-pharma-stocks-defy-market-slump-us-tariffs-exemption-2025-04-03/ Shorts can't fk with math: No one can : $NVO HAS 1 BILLION DOLLARS ON THE TABLE. THERE ARE : $LXRX 361,492,295 shares. $1 Billion from $NVO divided by: 361,492,295 $LXRX shares= $2.76 a $LXRX share. JUST ON THIS DEAL ALONE, DISCOUNTING THE NON OPIOD GOING ONTO PHASE 3. $HIMS $LLY $BIB
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Apr. 4 at 11:19 AM
$LXRX This has ZERO to do with being a 'good' or 'bad' trader. And EVERYTHING TO DO WITH SIMPLE MATH: $NVO HAS 1 BILLION DOLLARS ON THE TABLE. THERE ARE : $LXRX 361,492,295 shares. $1 Billion from $NVO divided by: 361,492,295 $LXRX shares= $2.76 a $LXRX share. JUST ON THIS DEAL ALONE, DISCOUNTING THE NON OPIOD GOING ONTO PHASE 3. https://www.investors.com/news/technology/novo-nordisk-lexicon-pharmaceuticals-obesity-treatment/ AND TO ADD TO ALL OF THAT: TARIFFS? PHARMA IS EXEMPT!!! Tariff exempt= "Trump imposed a 10% tariff on most U.S. imports, as well as much higher levies on dozens of rivals and allies alike, but temporarily exempted some goods, including pharmaceuticals, benefiting major exporters including India, Japan and Ireland." https://www.reuters.com/world/india/indian-pharma-stocks-defy-market-slump-us-tariffs-exemption-2025-04-03/ THE WORST POSSIBLE NIGHTMARE FOR A BEAR. NOW THE DEAL ON TOP OF HAVING A 1 BILLION VALUATION, BECOMES A SAFETY TRADE IN A DOWNTURN MARKET? LOL. YEAH, MANIPULATION MUCH: OF COURSE. BUT IT WON'T LAST VERY LONG. $LLY $HIMS $BIB
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Apr. 4 at 11:05 AM
$LXRX $HIMS $LLY $BIB $1 Billion divided by: 361,492,295 shares: $2.76 JUST ON THIS DEAL ALONE, DISCOUNTING THE NON OPIOD GOING ONTO PHASE 3. AND PHARMA IS EXEMPT. What Bears Know and Are Really Upset and Sad About = Deal= "Novo Nordisk will likely combine Lexicon's LX9851 with Wegovy, its GLP-1-focused weight-loss drug. Including milestone payments, the deal is worth up to $1 billion " https://www.investors.com/news/technology/novo-nordisk-lexicon-pharmaceuticals-obesity-treatment/ Tariff exempt= "Trump imposed a 10% tariff on most U.S. imports, as well as much higher levies on dozens of rivals and allies alike, but temporarily exempted some goods, including pharmaceuticals, benefiting major exporters including India, Japan and Ireland." https://www.reuters.com/world/india/indian-pharma-stocks-defy-market-slump-us-tariffs-exemption-2025-04-03/
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Apr. 4 at 11:01 AM
$LXRX $1 Billion divided by: 361,492,295 shares: $2.76 JUST ON THIS DEAL ALONE, DISCOUNTING THE NON OPIOD GOING ONTO PHASE 3. AND PHARMA IS EXEMPT. This is buyers wanting to buy on cheap and shit and egg on their face shorts. PUSH IT ALL THE WAY DOWN SO IT CAN CLIMB RIGHT BACK UP. DO IT. LOL, this clown. Shorts got their asses handed to them. All need to cheat this down, cuz they can't trade for shit. And try and cover for minimal loss. 3 dollar stock and Billion on the table, vs the shit you have to say? I'll stick with $NVO. I see 50,000 bid pre market at .40 cents, NOW WHO WANTS SO MANY SHARES OF SUCH A BIG PILE OF DOOKY YOU SAY THIS YOU POS fool. $HIMS $LLY $BIB
0 · Reply
truthseekr
truthseekr Apr. 2 at 2:16 PM
$LXRX This deal puts $LXRX at around 3 dollars a share, JUST ON THIS DEAL ALONE. $HIMS $LLY $BIB @novonordiskus + @LexPharma = 💪 $LXRX + $NVO "Novo Nordisk will likely combine Lexicon's LX9851 with Wegovy, its GLP-1-focused weight-loss drug." "Including milestone payments, the deal is worth up to $1 billion." https://www.investors.com/news/technology/novo-nordisk-lexicon-pharmaceuticals-obesity-treatment/
1 · Reply